Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis StudyZacks Investment Research • 03/19/24
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyGlobeNewsWire • 03/18/24
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street AnalystThe Motley Fool • 03/06/24
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 02/28/24
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving AverageZacks Investment Research • 02/27/24
Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High?Zacks Investment Research • 02/23/24
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/22/24
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & MoreZacks Investment Research • 02/21/24
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?The Motley Fool • 02/17/24
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisBusiness Wire • 02/15/24
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesGlobeNewsWire • 02/14/24
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of MedicineGlobeNewsWire • 01/31/24
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.The Motley Fool • 01/30/24
Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a TurnaroundZacks Investment Research • 01/29/24